Launched in China/Overseas or Under Marketing Application Review

Global
Global
Designated Asian Regions
Designated Asian Regions
Mainland China, HK SAR, Macao SAR and Taiwan
Mainland China, Hong Kong, Macao and Taiwan
China
China
Overseas
Overseas

Product Rights Authorized Region** Indication Clinical Trial Approval Clinical Trial for Registration Marketing Application Marketed Major Marketed Regions**
CN US EU JP
Diazepam Nasal Spray China Intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older

2023.6.7
Tildrakizumab Solution for Injection
(Biological Agent)
China Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

2023.5.26
Methotrexate Injection 中国 Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids

2023.3.24
Adult rheumatoid arthritis
Methylthioninium Chloride Enteric-coated Sustained-release Tablets China An diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy
Desidustat Tablets China Anemia in patients with chronic kidney disease
Cyclosporine Eye Drops 0.09% China Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)
PLENITY China
EU
An aid for weight management in adults with a BMI of 25-40 kg/m2 when used in conjunction with diet and exercise
Latanoprost Eye Drops China Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Ruxolitinib
cream
China
EU
Topical treatment of nonsegmental vitiligo in adults and pediatric patients aged 12 years of age and older
Topical short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
Levetiracetam XR Tablet China Adjunctive therapy for the treatment of partial-onset seizures
BCG for Intravesical Instillation
(Biological Agent)
China* Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence
PoNS China Chronic balance deficit due to mild-to-moderate traumatic brain injury

* Taiwan is not included in the rights authorized region of BCG for Intravesical Instillation
** Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region, CMS has NO development, commercialization or other product rights in unauthorized regions. Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 31 August 2023

Under R&D Stages

Global
Global
Designated Asian Regions
Designated Asian Regions
Mainland China, HK SAR, Macao SAR and Taiwan
Mainland China, Hong Kong, Macao and Taiwan
China
China
Overseas
Overseas

Product Rights Authorized Region** Indication Pre-clinical Clinical Trial Approval Phase I Phase II Phase III Marketing Application**
SDN – 037 China Eye pain and inflammation after cataract surgery
PDP – 716 China Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
CF101 China Psoriasis
ACT017
(Biological Agent)
China
Designated Asian Regions
Acute phase of ischemic stroke
CF102 China Hepatocellular carcinoma
Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis
XF – 73 China
Designated Asian Regions
Prevention of post-surgical staphylococcal infections
Infectious diseases
Y-3 injection China* Used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke
BB2603 China
EU
Onychomycosis and tinea pedis
VXM01
(Biological Agent)
China
EU
Recurrent glioblastoma
VEGF/ANG2 Tetravalent Bispecific Antibody
(Biological Agent)
Global Intended to be used for ocular fundus neovascular diseases
Nearly 10 innovative products under customization Global Including small molecules, monoclonal antibodies, bispecific antibodies, and siRNA products, etc.

* Taiwan is not included in the rights authorized region of Y-3 injection
** Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region, CMS has NO development, commercialization or other product rights in unauthorized regions. Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 31 August 2023